 |
GlaxoSmithKline settles US drug rows for $3bnGlaxoSmithKline has agreed in principle to settle its most significant disputes with the US government over the way it marketed and developed its drugs, at a cost of $3 billion, which is covered by existing provisions. The settlement, over More… |
 |
Bahrain withdraws diabetes drugProducts containing the diabetes drug Rosiglitazone have been ordered off Bahrain's shelves by the Health Ministry. It follows reports in Europe that pharmaceutical products such as Avandaryl, Avandamet and Avandia damage the heart and More… |
 |
Studies conflict on Glaxo diabetes drug riskTwo studies conducted in the US reported serious heart risks with GlaxoSmithKline Plc's diabetes pill Avandia while a third contradicted those findings, adding to a debate over whether the drug should stay on the market. The conflictin More… |
 |
Saudi suspends diabetes drug AvandiaSaudi Arabia has suspended GlaxoSmithKline's diabetes drug Avandia for six months, arguing that potential heart risks outweigh its benefits. The Saudi Food and Drug Authority (SFDA) was the first healthcare regulator to take such action. I More… |
 |
GSK defends drug against Senate reportGlaxoSmithKline, in response to a staff report of the US Senate, said that the report draws conclusions on the safety of its diabetes drug Avandia on analyses not consistent with the rigorous scientific evidence supporting the safety of the drug. More… |
 |
US senators seek withdrawal of Glaxo's AvandiaTwo US drug safety reviewers have recommended that GlaxoSmithKline's diabetes drug Avandia be pulled from the market after concluding it is more dangerous to the heart than a rival medicine. The Food and Drug Administration will again More… |
 |
Blockbuster Avandia and its side effectsThe last week of July had the Internet quite active with reports of how Glaxo SmithKline's blockbuster drug Avandia (rosiglitazone) and Eli Lilly/Takeda's Actos (pioglitazone) were being held responsible for a slew of side effects – right from bon More… |
 |
Glaxo diabetes drug to stay on marketGlaxoSmithKline's diabetes pill Avandia should stay on the the market even though data suggest it may raise the risk of a heart attack for some patients, US advisers said. Most of the advisory panel said the Food and Drug Administration sh More… |
|
Glaxo diabetes drug to stay on marketGlaxoSmithKline's diabetes pill Avandia should stay on the the market even though data suggest it may raise the risk of a heart attack for some patients, US advisers said. Most of the advisory panel said the Food and Drug Administration sh More… |
 |
Diabetes group urges caution on AvandiaThe latest studies on Avandia, GlaxoSmithKline's blockbuster diabetes drug, have raised enough questions about the drug's safety to worry the American Diabetes Association. Several studies now suggest the drug, which lowers blood sugar lev More… |
